Dimethyl sulfoxide (DMSO) attenuates the inflammatory response in the in vitro intestinal Caco-2 cell model |
| |
| Authors: | Hollebeeck Sylvie Raas Thomas Piront Neil Schneider Yves-Jacques Toussaint Olivier Larondelle Yvan During Alexandrine |
| |
| Affiliation: | a Life Science Institute, Catholic University of Louvain (UCL), B-1348 Louvain-la-Neuve, Belgium
b Research Unit of Cellular Biology, URBC - NARILIS, University of Namur - FUNDP, 61 rue de Bruxelles, B-5000 Namur, Belgium |
| |
| Abstract: | This study aimed to investigate dose effects of dimethyl sulfoxide (DMSO) (0.05-1%) on the intestinal inflammatory response in confluent- and differentiated-Caco-2 cells stimulated with interleukin (IL)-1β or a pro-inflammatory cocktail for 24 h. Cyclooxygenase-2 (COX-2) activity was assayed by incubating inflamed cells with arachidonic acid and then measuring prostaglandin-E2 (PGE2) produced. Soluble mediators (IL-8, IL-6, macrophage chemoattractant protein-1 (MCP-1), and COX-2-derived PGE2) were quantified by enzyme immunoassays and mRNA expression of 33 proteins by high throughput TaqMan Low Density Array. Data showed that DMSO decreased induced IL-6 and MCP-1 secretions in a dose-dependent manner (P < 0.05), but not IL-8; these effects were cell development- and stimulus- independent. Moreover, in IL-1β-stimulated confluent-cells, DMSO dose-dependently reduced COX-2-derived PGE2 (P < 0.05). DMSO at 0.5% decreased significantly mRNA levels of 14 proteins involved in the inflammatory response (including IL-6, IL-1α, IL-1β, and COX-2). Thus, DMSO at low concentrations (0.1-0.5%) exhibits anti-inflammatory properties in the in vitro intestinal Caco-2 cell model. This point is important to be taken into account when assessing anti-inflammatory properties of bioactive compounds requiring DMSO as vehicle, such as phenolic compounds, in order to avoid miss-interpretation of the results. |
| |
| Keywords: | COX, cyclooxygenase d, day DMS, dimethyl sulfide DMSO, dimethyl sulfoxide DMSO2, methyl sulfone IBD, inflammatory bowel disease ICAM-1, intercellular adhesion molecule 1 IFNGR1, interferon gamma receptor 1 IECs, intestinal epithelial cells IL, interleukin ILR, interleukin receptor IFN-γ, interferon gamma iNOS, inducible nitric oxide synthase LDH, lactate dehydrogenase LPS, lipopolysaccharide MAPK, mitogen-activated protein kinase MIP, macrophage inflammatory protein MCP-1, monocyte chemotactic protein-1 NF-κB, nuclear factor κB NOD2, nucleotide-binding oligomerization domain containing 2 PGE2, prostaglandin E2 PLA2, phospholipase A2 PPAR, peroxisome proliferator-activated receptor RANTES, chemokine (C-C motif) ligand 5 SOD2, superoxide dismutase 2 TLDA, TaqMan Low Density Array TNFα, tumor necrosis factor alpha VCAM-1, vascular cell adhesion protein 1 |
| 本文献已被 ScienceDirect PubMed 等数据库收录！ |
|
